Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lexaria BioscienceLEXX +3.69%22 PS Ratio is 54.01 as of Jul. 28, 2026, which is 24% below its 10-year median of 71.51. GuruFocus rates LEXX with a GF Score™ of 22/100 and a GF Value™ of $0.37 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 929 Biotechnology companies, Lexaria Bioscience ranks worse than 79.22% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lexaria Bioscience's share price is $0.5401.
Lexaria Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 was $0.01. Hence, Lexaria Bioscience's PS Ratio for today is 54.01.
The historical rank and industry rank for Lexaria Bioscience's PS Ratio or its related term are showing as below:
LEXX'
s PS Ratio Range Over the Past 10 Years
Min: 13.66 Med: 71.51 Max: 1496.07
Current: 54.01
During the past 13 years, Lexaria Bioscience's highest PS Ratio was 1496.07. The lowest was 13.66. And the median was 71.51.
LEXX's PS Ratio is ranked worse than 79.22% of 929
companies
in the Biotechnology industry
Industry Median: 9.06
vs LEXX: 54.01
Lexaria Bioscience Corp revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Lexaria Bioscience was -72.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -3.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -27.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 4.90% per year.
During the past 13 years, Lexaria Bioscience's highest 3-Year average Revenue per Share Growth Rate was 155.30% per year. The lowest was -83.20% per year. And the median was -8.55% per year.
Back to Basics: PS Ratio
Lexaria Bioscience (NAS:LEXX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lexaria Bioscience PS Ratio Related Terms
Lexaria Bioscience PS Ratio Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lexaria Bioscience's Share Price of today is $0.5401. Lexaria Bioscience's Revenue per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lexaria Bioscience (LEXX) has a PS Ratio of 54.01 as of Jul. 28, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lexaria Bioscience and its competitors. This is 24% below median its historical median of 71.51. Over the past decade, Lexaria Bioscience's PS Ratio has ranged from 13.66 to 1,496.07. According to the industry distribution chart, Lexaria Bioscience ranks #736 out of 929 companies in the Biotechnology industry, placing it in the top 79.2%.
Is Lexaria Bioscience's PS Ratio too high?
Lexaria Bioscience's current PS Ratio of 54.01 is 24% below median its 10-year median of 71.51. Over the past 10 years, this metric has ranged from a low of 13.66 to a high of 1,496.07. The Biotechnology industry median PS Ratio is 9.06. Lexaria Bioscience's value of 54.01 is 496.1% above this industry median. Based on the distribution chart, Lexaria Bioscience ranks #736 out of 929 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's PS Ratio compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #736 out of 929 companies for PS Ratio. This places Lexaria Bioscience in the lower half of its industry. The industry median PS Ratio is 9.06. Lexaria Bioscience's value of 54.01 is 496.1% above this benchmark. Historically, Lexaria Bioscience's own PS Ratio has ranged from 13.66 to 1,496.07 over the past decade. While the company's 10-year median is 71.51 vs. the industry median of 9.06, Lexaria Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.06, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current PS Ratio of 54.01 is 496.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lexaria Bioscience and its competitors. For the Biotechnology industry, the median PS Ratio is 9.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current PS Ratio is 54.01, which is 24% below median its own 10-year median of 71.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $0.54 — trading 46% above its estimated fair value. The current PS Ratio is 54.01, which is 24% below median its 10-year median of 71.51 and 496.1% above the Biotechnology industry median of 9.06. Lexaria Bioscience's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current PS Ratio is 54.01 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $0.54 is trading 46% above its estimated GF Value™ of $0.37.
GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.
Key valuation signals for LEXX:
PS Ratio: 54.01 (24% below median its 10-year median of 71.51)
GF Value™: $0.37 vs. price of $0.54 (46% above fair value)
Industry Position: 496.1% above the Biotechnology median (#736 of 929)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score
Get the complete analysis for LEXX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
